Pharmaron Beijing Co., Ltd.

300759

CNE100003JW4

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
18.46 ^CNY	+1.60%		+1.21%	-36.30%

Apr. 08	Pharmaron Partners Seven Firms to Float 2 Billion Yuan Fund	MT
Mar. 28	Pharmaron's 2023 Profit, Revenue Rise; Misses Estimates	MT

LinkStart SMO, Ltd. announced that it has received funding from Pharmaron Beijing Co., Ltd.

June 17, 2019

LinkStart SMO, Ltd. announced that it has raised a round of funding on June 18, 2019. the transaction included participation from new strategic investor Pharmaron Beijing Co., Ltd. (SZSE:300759).

Latest news about Pharmaron Beijing Co., Ltd.

Pharmaron Partners Seven Firms to Float 2 Billion Yuan Fund	Apr. 08	MT
Pharmaron's 2023 Profit, Revenue Rise; Misses Estimates	Mar. 28	MT
Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023	Mar. 27	CI
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Nomura Adjusts Pharmaron Beijing’s Price Target to HK$17.99 From HK$30.92, Keeps at Buy	Mar. 06	MT
Pharmaron Beijing Sees Up to 14% Jump in 2023 Profit	Jan. 29	MT
Pharmaron Forecasts Up to 19% Rise in 2023 Attributable Profit	Jan. 29	MT
Pharmaron Beijing Co., Ltd. Provides Earnings Guidance for the Financial Year Ended December 31, 2023	Jan. 28	CI
Pharmaron Beijing Buys Back Additional Series 2 Bonds	Jan. 15	MT
Pharmaron Beijing Buys Back $68 Million of Convertible Bonds Due 2026	Jan. 12	MT
Pharmaron Beijing Buys Back 705 Million Yuan of Series 2 Bonds Due 2026	Jan. 12	MT
Pharmaron's Q3 Attributable Profit Rises 6%; Shenzhen Shares Surge 12%	23-10-30	MT
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-29	CI
Nomura Adjusts Pharmaron’s Price Target to 61.24 Yuan From 66.94 Yuan, Keeps at Buy	23-10-25	MT
Pharmaron's Profit Climbs 34.3% in H1	23-08-28	MT
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27	CI
Pharmaron Beijing's Profit to Jump Up to 36% in H1; Shares Jump 10%	23-07-31	MT
Pharmaron Slashes Conversion Price of Zero-Coupon Convertible Bonds Due 2026	23-07-26	MT
Nomura Adjusts Pharmaron’s Price Target to 66.94 Yuan From 73.38 Yuan, Keeps at Buy	23-07-24	MT
Nomura Adjusts Pharmaron’s Price Target to HK$36.24 From HK$40.03, Keeps at Buy	23-07-24	MT
Pharmaron Beijing Co., Ltd. Announces Final Dividend on A Shares for the Year 2022, Payable on July 27, 2023	23-07-20	CI
Pharmaron Beijing Co., Ltd. Approves Cash Dividend for 2022	23-06-26	CI
Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 18 August 2023	23-05-25	CI
Nomura Adjusts Pharmaron’s Price Target to 73.38 Yuan From 85.63 Yuan, Keeps at Buy	23-04-28	MT
Nomura Adjusts Pharmaron's Price Target to HK$60.04 From HK$69.02, Keeps at Buy	23-04-28	MT

Chart Pharmaron Beijing Co., Ltd.

Duration

Period

More charts

Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows: - laboratory services (61.3%); - development and production of chemical processes and formulations (23.5%); - clinical research services (12.8%); - other (2.4%); Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).

Sector

Biotechnology & Medical Research

Calendar

2024-04-24 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Pharmaron Beijing Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

18.46 CNY

Average target price

25.3 CNY

Spread / Average Target

+37.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMARON BEIJING CO., LTD.	-36.30%	4.13B
IQVIA HOLDINGS INC.	+3.13%	43.43B
LONZA GROUP AG	+48.83%	41.69B
MODERNA, INC.	+8.49%	41.31B
CELLTRION, INC.	-10.82%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.26%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-23.69%	18.47B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.58%	12.33B
MEDPACE HOLDINGS, INC.	+32.83%	12.59B
UNITED THERAPEUTICS CORPORATION	+6.63%	11.03B

Other Biotechnology & Medical Research

Pharmaron Beijing Co., Ltd.

Equities

300759

CNE100003JW4

Biotechnology & Medical Research

LinkStart SMO, Ltd. announced that it has received funding from Pharmaron Beijing Co., Ltd.

Latest news about Pharmaron Beijing Co., Ltd.

Chart Pharmaron Beijing Co., Ltd.

Company Profile

Income Statement Evolution

Ratings for Pharmaron Beijing Co., Ltd.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research